Hemapheresis in systemic lupus erythematosus

Area of Science:

• Rheumatology
• Immunology
• Nephrology

Background:

• The role of plasma exchange (PE) in treating systemic lupus erythematosus (SLE) is still under investigation.
• Current data suggest PE may benefit specific severe SLE subsets, such as those with central nervous system (CNS) involvement, crescentic glomerulonephritis, and lupus vasculitis.
• PE may also be relevant for certain anti-phospholipid syndrome manifestations.

Purpose of the Study:

• To discuss the current place of plasma exchange in SLE treatment.
• To explore the potential benefits and limitations of PE in severe SLE and anti-phospholipid syndrome.
• To highlight areas for future research regarding PE efficacy and novel therapeutic approaches.

Main Methods:

• Review of available clinical data on plasma exchange in SLE.
• Discussion of adjunctive therapies including conventional treatments, cyclophosphamide pulses, and selective removal techniques.
• Analysis of biological marker changes versus clinical outcomes.

Main Results:

• Plasma exchange may be a useful addition in specific severe SLE cases (CNS, glomerulonephritis, vasculitis) and anti-phospholipid syndrome.
• A discrepancy exists between rapid biological improvements (e.g., ds-DNA antibodies) and parallel clinical benefits, requiring further investigation.
• Synchronization of PE with cyclophosphamide and selective removal of pathogenic substances are potential therapeutic avenues.

Conclusions:

• Plasma exchange's role in SLE requires further clarification, particularly regarding its impact on clinical outcomes.
• Selective removal of pathogenic antibodies or immune complexes presents a promising strategy for understanding SLE pathogenesis.
• More data are needed to interpret the efficacy of combined PE and cyclophosphamide therapies.